The economic argument for longevity science is ultimately a health span argument. Global healthcare spending is dominated by the last decade of life, much of it consumed by chronic, multi-morbid conditions; heart failure, dementia, osteoarthritis, frailty, that current medicine manages but does not resolve.
If interventions that target the aging process can delay the onset of these conditions by even a few years across a population, the savings in direct medical costs, caregiving burden, and lost productivity would be substantial, independent of any effect on maximum lifespan. This is why economists and public-health researchers increasingly describe aging research not as a luxury pursuit for the wealthy, but as one of the highest-leverage investments available in preventive medicine.
Demographic trends make this urgency concrete. The global population aged 60 and above is on track to nearly double by 2050, and the cohort aged 80 and older is expected to more than triple over the coming decades. Population aging is fastest in regions that are least prepared for it, straining pension systems, long-term care infrastructure, and health workforces simultaneously.
Any technology that meaningfully delays age-related decline --- even modestly would ease pressure across each of these systems at once, which is precisely the kind of broad, structural benefit that justifies sustained public and private investment rather than treating longevity as a niche consumer wellness category.